Envita Patient Expresses Joy at Outliving Her Cancer Prognosis on Fox10 News

Exactly a year ago, Tammy Morrow, a stage 4 breast cancer patient, was told that she had only two months to live, but she defied this prognosis with advanced precision oncology treatments, making this holiday season extra special for her family. "It was absolutely a turning point, I will say, that saved my life," said Tammy, in the Fox10 report, referring to her decision to pursue care at Envita Medical Centers, a Center of Excellence for precision integrative oncology.

Tammy had experienced severe side effects with standard oncology treatments, which is why she had started looking for targeted integrative oncology options. “Many times cancer patients are feeling that they are killing the cancer, but they're killing themselves just as fast," said Dr. John Oertle, Chief Medical Director, Envita Medical Centers. Unlike the one-size-fits-all regimens in standard oncology, the team at Envita custom develops treatment protocols, based on each individual patient. These personalized precision treatment protocols are designed to target the cancerous cells, minimize impact to the surrounding healthy cells, and reactivate the patient's immune system to help them sustain lasting outcomes.

“[They] target the chemotherapy and make it fractionated, so it was very small, and I could tolerate it and still work full-time," added Tammy, expressing gratitude to the Envita team for the outcome she experienced here. She benefitted greatly from Envita's proprietary treatments like GTFC™ (Genetically Targeted Fractionated Chemotherapy), which unlike standard chemotherapy, is based on detailed analysis of genomics, proteomics, immune status, and multiple other factors.

To know more about Tammy's journey to recovery and how Envita's innovative treatment approach helped her outlive her prognosis, watch this report.